186 related articles for article (PubMed ID: 12736246)
1. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
2. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
3. A fusion protein with improved thrombolytic effect and low bleeding risk.
Wang X; Zhang G; Wang L; Zhang Q; Qin Y; Wu C; Yu A
Thromb Haemost; 2009 Dec; 102(6):1194-203. PubMed ID: 19967151
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Collen D; De Cock F; Stassen JM
Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
[TBL] [Abstract][Full Text] [Related]
5. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
6. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
Aisina RB; Moukhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
[TBL] [Abstract][Full Text] [Related]
7. Design of a thrombin inhibitory staphylokinase based plasminogen activator with anti-reocclusion potential.
Arora K; Maheshwari N; Sahni G
Int J Biol Macromol; 2020 Feb; 144():791-800. PubMed ID: 31739007
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a multifunctional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJ1158.
Kumar A; Pulicherla KK; Mayuren C; Kotra S; Rao KR
Can J Physiol Pharmacol; 2013 Oct; 91(10):839-47. PubMed ID: 24144055
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
10. A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy.
Wu SC; Castellino FJ; Wong SL
J Biol Chem; 2003 May; 278(20):18199-206. PubMed ID: 12646571
[TBL] [Abstract][Full Text] [Related]
11. Effect of hirudin on tissue plasminogen activator induced clot lysis.
Electricwala A; Atkinson T
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):267-71. PubMed ID: 2129413
[TBL] [Abstract][Full Text] [Related]
12. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
[TBL] [Abstract][Full Text] [Related]
13. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
15. New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats.
Szemraj J; Zakrzeska A; Brown G; Stankiewicz A; Gromotowicz A; Grędziński T; Chabielska E
Pharmacol Rep; 2011; 63(5):1169-79. PubMed ID: 22180359
[TBL] [Abstract][Full Text] [Related]
16. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
19. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
20. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; von Hodenberg E; Newell JB; Kübler W; Haber E; Runge MS
Circulation; 1994 Oct; 90(4):1956-63. PubMed ID: 7923685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
